The estimated Net Worth of Ronald Harold Wilfred Cooper is at least $5.74 Million dollars as of 23 January 2023. Mr. Cooper owns over 1,057 units of Albireo Pharma Inc stock worth over $2,536,153 and over the last 8 years he sold ALBO stock worth over $208,898. In addition, he makes $2,995,410 as President, Chief Executive Officer, and Director at Albireo Pharma Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Cooper ALBO stock SEC Form 4 insiders trading
Ronald has made over 8 trades of the Albireo Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,057 units of ALBO stock worth $46,297 on 23 January 2023.
The largest trade he's ever made was exercising 11,973 units of Albireo Pharma Inc stock on 17 September 2021 worth over $229,762. On average, Ronald trades about 734 units every 56 days since 2016. As of 23 January 2023 he still owns at least 57,444 units of Albireo Pharma Inc stock.
You can see the complete history of Mr. Cooper stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Cooper biography
Ronald Harold Wilfred Cooper is the President, Chief Executive Officer, Director of Albireo Pharma Inc. He served as President and Chief Executive Officer of Albireo Limited from July 2015 until November 2016 and has served as a director of Albireo Limited since September 2015. Prior to joining Albireo, Mr. Cooper worked for over 25 years in successive leadership roles at Bristol-Myers Squibb Company, a global biopharmaceutical company. Most recently, at Bristol-Myers Squibb Company, Mr. Cooper served as President, Europe from May 2010 until November 2015; President, Northern and Central Europe from April 2009 until April 2010; and Senior Vice President and General Manager, EU Markets from January 2008 until March 2009. Previously, Mr. Cooper held multiple senior roles in the U.S. and other countries. Mr. Cooper has served on the board of directors of Genocea Biosciences, Inc., a publicly traded biopharmaceutical company, since June 2016. Mr. Cooper earned his Bachelor's degree in Chemistry and Business Administration from St. Francis Xavier University in Canada.
What is the salary of Ronald Cooper?
As the President, Chief Executive Officer, and Director of Albireo Pharma Inc, the total compensation of Ronald Cooper at Albireo Pharma Inc is $2,995,410. There are no executives at Albireo Pharma Inc getting paid more.
How old is Ronald Cooper?
Ronald Cooper is 57, he's been the President, Chief Executive Officer, and Director of Albireo Pharma Inc since 2016. There are 12 older and 7 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
What's Ronald Cooper's mailing address?
Ronald's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN, MA, 02472.
Insiders trading at Albireo Pharma Inc
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs, and Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
What does Albireo Pharma Inc's logo look like?
Complete history of Mr. Cooper stock trades at Albireo Pharma Inc, Genocea Biosciences Inc, Generation Bio Co, and C4 Therapeutics
Albireo Pharma Inc executives and stock owners
Albireo Pharma Inc executives and other stock owners filed with the SEC include:
-
Ronald Cooper,
President, Chief Executive Officer, Director -
Pamela Stephenson,
Chief Commercial Officer -
Jan Mattsson,
Chief Scientific Officer -
Martha Carter,
Chief Regulatory Officer -
Ronald H. W. Cooper,
CEO, Pres & Director -
Patrick Horn,
Chief Medical Officer -
Martha J. Carter,
Chief Regulatory Officer -
Simon Nicolas Reade Harford,
CFO & Treasurer -
David Chiswell,
Independent Chairman of the Board -
Davey Scoon,
Independent Director -
Michael Gutch,
Independent Director -
Roger Jeffs,
Independent Director -
Stephanie Okey,
Independent Director -
Anne Klibanski,
Independent Director -
Jason Duncan,
Chief Legal Officer, General Counsel, Secretary -
Michelle Graham,
Chief Human Resource Officer -
Simon Harford,
Chief Financial Officer, Treasurer -
Jason G. Duncan,
Chief Legal Officer, Gen. Counsel & Sec. -
Pamela Stephenson M.P.H.,
Chief Commercial Officer -
Dr. Kristina Torfgard,
VP & Global Project Head -
Michelle Graham,
Chief HR Officer -
Joan Connolly,
Chief Technology Officer -
Dr. Jan P. Mattsson Ph.D.,
Chief Scientific Officer, MD (Sweden) & Co-Founder -
Dr. Per-Goran Gillberg,
Co-Founder & VP of Devel. -
Denise Scots Knight,
Director -
Julia R Brown,
Director -
Heather Preston,
Director -
Paresh Soni,
Chief Medical Officer -
Thomas A. Shea,
CFO and Treasurer -
Peter A Zorn,
Senior VP, Corp Dev, GC & Sec -
Plcastrazeneca Ab Astrazeneca,
-
Paul Streck,
Chief Medical Officer -
Advisors Llcperceptive Life...,
-
Partners Ltd Phase4 Venture...,
-
Craig C. Hopkinson,
Director -
Susan Alesina,
Director -
Habib J Dable,
Director